---
title: "Health-Related QOL | Kisqali®"
description: "Explore how quality of life was preserved with KISQALI + NSAI vs NSAI alone over 3 years in premenopausal women with HR+/HER2− EBC."
canonical_url: "https://www.kisqali.com/early-breast-cancer/health-related-quality-of-life"
meta:
  "og:description": "Explore how quality of life was preserved with KISQALI + NSAI vs NSAI alone over 3 years in premenopausal women with HR+/HER2− EBC."
  "og:title": "Health-Related QOL"
---

## **Maintained QOL**

### **KISQALI + AI maintained quality of life ***vs*** AI alone at 3 years. \***<sup>(1)</sup>

In the NATALEE study, physical functioning from the EORTC QLQ-C30 was the prespecified primary HR-QOL outcome of interest. <sup>(1)</sup>

|  | | |
| --- | --- | --- |
| Physical functioning | Global health status | Social functioning |
| Maintained | Maintained | Maintained |
| KISQALI + AI: -1.50 | KISQALI + AI: +3.10 | KISQALI + AI: 0.26 |
|  | AI alone: -1.96 | |

QOL was assessed using the EORTC QLQ-C30 questionnaire, a validated tool used worldwide to assess QOL in patients with cancer. QoL was a secondary endpoint measured by patient-reported outcomes and was assessed at baseline and throughout treatment. <sup>(1)</sup>  
  
 \* The EORTC QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status/QOL scale and a number of single items. <sup>(2)</sup>  
  
<sup>†</sup> No difference from baseline was observed in either arm based on established thresholds for interpreting changes in physical functioning score (−5 to 2, no difference).

## Sitemap

See the full [sitemap](/sitemap.md) for all pages.